Skip to main content

Table 1 Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

From: Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

  Biomarkers The predictive effect of biomarkers Reference
Tumor feature PD-L1 expression level 15.4 months, 95%CI: 10.6–18.8 months
(median OS)
53%, 95%CI: 30–75%
(DCB)
HR: 0.63, 95%CI: 0.47–0.86
(OS)
[22,23,24]
TMB tTMB
29 vs. 6%
(ORR)
HR: 0.62, 95%CI: 0.38–1.00
(PFS)
HR: 0.58, 97.5%CI: 0.41–0.81
(PFS)
bTMB
HR: 0.39, 95%CI: 0.18–0.84
(PFS)
[28, 30,31,32]
Neoantigens HR: 0.23, 95%CI: 0.09–0.58
(median PFS)
92 vs. 11%
(DCB)
[34, 42]
Driver gene mutations KRAS
OR: 1.51; 95%CI: 1.17–1.96
(ORR)
TP53
HR: 0.32, 95%CI: 0.16–0.63
(PFS)
EGFR
5.3 months, 95%CI: 1.3–12.4 months
(median PFS)
ALK
0.6 months, 95% CI: 0.2–2.1 months
(PFS)
MET
17%, 95%CI: 6%-36%
(ORR)
NFE2L2/KEAP1
22.52 months vs. 12.89 months
(median OS)
[46, 47, 51, 53, 55, 61]
miRNA HR: 0.45, 95%CI: 0.25–0.76
(median PFS)
HR: 0.39, 95%CI: 0.15–0.68
(median OS)
[71]
Tumor microenvironment TIL HR: 0.954, 95%CI: 0.965–0.983
(DFS)
HR: 0.965, 95%CI: 0.931–1.001
(OS)
[78]
Biomarkers in peripheral blood CAMLs HR: 2.5, 95%CI: 1.1–5.8
(PFS)
HR: 3.5, 95%CI: 1.3–9.6
(OS)
[109]
CTECs 5 months, 95%CI: 3.9–6.1 months
(median PFS)
[116]
Other peripheral blood cells NLR
HR: 1.44, 95%CI: 1.26–1.65
(median PFS)
HR: 2.86, 95%CI: 2.11–3.87
(median OS)
[119]
Other Gut microbiota HR: 4.2, 95%CI: 1.42–12.3
(PFS)
[130]
Patients clinical characteristics Gender
male: HR: 0.76, 95%CI: 0.64–0.91
female: HR: 0.44, 95%CI: 0.25–0.76
(OS)
Smoking
36 vs. 26 vs. 14%
(current smokers vs. former smokers vs. non-smokers)
PIOS
HR: 0.469, 95%CI: 0.295–0.747
(median PFS)
HR: 0.539, 95%CI: 0.317–0.918
(median OS)
[141, 142, 144]
  1. PD-L1 programmed cell death ligand 1, CI confidence interval, OS overall survival, DCB durable clinical benefit, TMB tumor mutational burden, ORR objective response rate, HR hazard ratio, PFS progression-free survival, KRAS kirsten rat sarcoma 2 viral oncogene homolog, OR odds ratio, TP53 tumor protein p53, EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, MET mesenchymal epithelial transition, KEAP1 kelch-like ECH-associated protein 1, NFE2L2 nuclear factor erythroid-2-related factor-2, TIL tumor-infiltrating lymphocyte, DFS disease-free survival, CAMLs circulating cancer-associated macrophage-like cells, CTECs circulating tumor endothelial cells, NLR neutrophil to lymphocyte ratio, PIOS patras immunotherapy score